SS-31 (Elamipretide) · Research brief

SS-31 (Elamipretide): Mitochondrial Peptide Research Guide

Real Peptides Research TeamEditorial

Updated September 5, 20269 min read

53 WORDS

Short answer

SS-31 (elamipretide) is a synthetic, water-soluble tetrapeptide from the Szeto-Schiller peptide series. It carries an alternating aromatic-cationic sequence that lets it accumulate in the inner mitochondrial membrane, where it associates with the phospholipid cardiolipin. Research examines its effects on mitochondrial bioenergetics, membrane organization and oxidative stress across cardiac, renal, neurological and rare-disease models.

Key takeaways

SS-31 (elamipretide) is a synthetic, water-soluble tetrapeptide from the Szeto-Schiller series that concentrates in the inner mitochondrial membrane, where it associates with cardiolipin.
The mechanism most often described in the literature involves stabilizing cardiolipin-containing membranes and supporting electron transport chain organization; a 2024 CRISPR screen also identified phospholipid scramblase 3 as a biological target.
Published work spans cardiac, renal, neurological, skeletal and rare mitochondrial disease models, including a 168-week open-label extension of the TAZPOWER study in Barth syndrome.
Elamipretide received a first regulatory approval reported in 2026; material sold by research suppliers is not approved for the exploratory uses discussed here and is supplied for laboratory research only.
Lyophilized peptide is typically stored cold and protected from light, reconstituted with an appropriate sterile diluent, and kept refrigerated for short-term use with aliquoting to limit freeze-thaw cycles.
Supplier evaluation rests on per-batch third-party COAs, HPLC purity chromatograms, mass spectrometry identity confirmation, and traceable lot numbers.

What SS-31 Is and Where It Came From

The Szeto-Schiller (SS) peptides emerged from work on opioid-peptide analogs, where researchers noticed that certain short aromatic-cationic sequences distributed into cells and concentrated inside mitochondria without requiring a membrane potential to get there. SS-31 became the most studied member of that family. Its clinical development name is elamipretide; older literature and vendor catalogs also list it as MTP-131 or Bendavia.

Structurally it is a four-residue peptide with an unusual alternating pattern of aromatic and basic side chains. That arrangement gives it a net positive charge and a hydrophobic face at the same time — the combination that drives its partitioning into the inner mitochondrial membrane, an anionic, cardiolipin-rich environment. Unlike triphenylphosphonium-conjugated mitochondrial agents, SS-31 does not depend on the mitochondrial membrane potential for uptake, which is one reason it has drawn attention in models where that potential is already collapsing.

A 2025 review in the International Journal of Molecular Sciences covers the structure, mechanism and therapeutic potential of elamipretide in depth, and a companion 2025 review in Biomedicine & Pharmacotherapy surveys contemporary insights into its mitochondrial mechanism. Those two papers are the natural starting point for anyone building background on the compound.

Reported Mechanism of Action

The dominant model in the literature is cardiolipin binding. Cardiolipin is a four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane, where it helps shape cristae curvature, anchors cytochrome c, and supports the assembly of respiratory chain complexes into supercomplexes. When cardiolipin is depleted, remodeled abnormally, or peroxidized — as happens in ischemia, aging, and certain genetic conditions — cristae architecture and electron transport efficiency degrade together.

SS-31 is described as associating with cardiolipin-containing membranes and, in doing so, helping preserve that organization. Reported downstream consequences in experimental systems include improved electron flux, reduced electron leak and reactive oxygen species generation, better retention of cytochrome c, and preserved cristae morphology on electron microscopy. Importantly, the peptide is generally characterized as a membrane-interacting agent rather than a classical antioxidant scavenger.

Beyond cardiolipin: a genetically identified target

A 2024 genome-wide CRISPR screen published in the Journal of the American Society of Nephrology identified phospholipid scramblase 3 as a biological target of SS-31. Phospholipid scramblase 3 participates in cardiolipin trafficking between mitochondrial membranes, so the finding fits the lipid-centric picture while adding a defined protein node to it. It also gives the field something it had been missing: a genetic handle for testing mechanism rather than inferring it from phenotype alone.

Ferroptosis and cell-death pathways

More recent work has connected mitochondrial lipid protection to ferroptosis, the iron-dependent, lipid-peroxidation-driven form of cell death. A 2026 Neurotherapeutics paper reports that SS-31 improved post-cardiac-arrest brain injury in a model system by inhibiting microglial ferroptosis and shifting microglial polarization. A 2025 Biomedicine & Pharmacotherapy study describes a mitochondria-targeted SS-31 and ferrostatin-1 construct alleviating ferroptosis in hypoxia/reoxygenation cardiomyocytes. Both are early-stage findings, and the mechanistic link between membrane stabilization and ferroptosis suppression is still being worked out.

What the Research Literature Examines

The published work clusters into several areas. Across all of them, the honest summary is that preclinical signals have been more consistent than clinical translation, and that evidence remains preliminary outside of narrow indications.

Cardiac and ischemia-reperfusion research

Cardiac tissue has extraordinary mitochondrial density and cardiolipin content, which made it an obvious early target. Preclinical work in rodent and larger-animal models has examined infarct size, contractile recovery after reperfusion, and mitochondrial respiration in isolated cardiac fibers. The 2025 hypoxia/reoxygenation cardiomyocyte study noted above sits in this lineage. Clinical work in heart failure has been conducted, and results across trials have been mixed rather than uniformly positive — a point worth holding onto when reading enthusiastic secondary coverage.

Renal research

Kidney proximal tubules are similarly mitochondria-dense, and renal ischemia-reperfusion and chronic kidney injury models have generated a substantial body of SS-31 literature. The 2024 JASN CRISPR paper emerged from this space, which reflects how central nephrology research has been to mechanistic understanding of the peptide.

Rare mitochondrial disease

The most developed clinical dataset concerns Barth syndrome, a genetic disorder of cardiolipin remodeling caused by TAZ mutations. A 2024 report in Genetics in Medicine presented 168-week open-label extension results from the TAZPOWER study, describing long-term efficacy and safety observations in participants with Barth syndrome. A 2026 Drugs article titled "Elamipretide: First Approval" documents that elamipretide reached an initial regulatory approval — a meaningful milestone, and one that applies to a specific approved indication and formulation, not to the broad exploratory uses discussed across the research literature.

Neurological research

Neurons are metabolically demanding and vulnerable to mitochondrial failure, so models of ischemic brain injury, neurodegeneration and neuroinflammation have been explored. The 2026 post-cardiac-arrest brain injury work is the clearest recent example. This area remains early.

Aging, musculoskeletal and stem cell biology

A 2025 paper in Organogenesis reports that SS-31 targeted NOS2 to enhance osteogenic differentiation in aged bone marrow stromal cells by restoring mitochondrial function. Related lines of inquiry examine skeletal muscle bioenergetics and age-associated decline in mitochondrial capacity. These are cell and animal studies; extrapolation beyond them is not supported.

Research area	Typical model systems	Maturity of evidence
Cardiac ischemia-reperfusion	Isolated cardiomyocytes, rodent and large-animal models	Extensive preclinical; clinical results mixed
Renal injury	Tubular cell culture, rodent ischemia and CKD models	Extensive preclinical; mechanism-defining work
Barth syndrome	Human open-label clinical extension (TAZPOWER)	Most developed clinical dataset
Neurological injury	Post-cardiac-arrest and microglial models	Early, preclinical
Aging and skeletal biology	Aged BMSCs, muscle preparations	Early, preclinical

Laboratory Handling in General Terms

SS-31 is supplied as a lyophilized white powder under vacuum or inert gas. Handling practice mirrors that of other small hydrophilic peptides, and the details below are general laboratory conventions rather than protocol instructions.

Receiving and storage of powder. Lyophilized material is typically kept cold and protected from light and moisture. Vials are usually allowed to reach room temperature before opening so condensation does not settle on the cake.
Reconstitution. The peptide is readily water-soluble. Laboratories generally introduce sterile diluent slowly down the vial wall rather than directly onto the powder, then allow dissolution by gentle swirling. Vigorous shaking is avoided because mechanical shear and foaming can degrade peptides.
Post-reconstitution storage. Solutions are typically refrigerated for short-term use. For longer intervals, aliquoting into single-use portions limits repeated freeze-thaw cycles, which are a common and avoidable source of potency loss.
Documentation. Recording lot number, reconstitution date, diluent identity and concentration on the vial and in the lab notebook is what makes a result reproducible months later.

Companion articles on this site cover reconstitution math, storage timelines, and vial handling in step-by-step detail for laboratory personnel who need them.

Regulatory and Research-Use Status

This point deserves plain language. Elamipretide has been reported to receive a first regulatory approval in a defined clinical context, but SS-31 material distributed by research peptide suppliers is not an approved drug product, is not FDA-approved for any of the exploratory applications described in the literature above, and is not intended for human or veterinary use. It is supplied for laboratory research use only, by qualified personnel, in appropriate facilities, under applicable institutional oversight.

Nothing in the published literature summarized here should be read as a therapeutic claim. Preclinical findings in cells and animals frequently fail to reproduce in human trials, and elamipretide's own clinical history illustrates exactly that gap.

How Researchers Evaluate Supplier Quality

Peptide quality is the single largest uncontrolled variable in most independent research. A rigorous supplier makes that variable checkable.

Per-batch third-party COA. The certificate should correspond to the specific lot in hand, not a representative or historical batch, and should come from an independent analytical laboratory.
HPLC purity with a visible chromatogram. A purity percentage alone is weak evidence. The chromatogram shows peak shape, retention time and the size of nearby impurity peaks — information a single number hides.
Mass spectrometry identity. Purity confirms homogeneity; mass spec confirms the molecule is actually the intended tetrapeptide, with observed mass matching theoretical mass.
Batch traceability. Lot numbers printed on the vial that match the COA, with retained records, allow a researcher to trace an anomalous result back to material.
Supporting specifications. Depending on the application, laboratories may also look for water content, residual solvent, acetate content, and endotoxin data.

Real Peptides publishes COAs per batch for this reason: reproducibility begins with knowing precisely what was in the vial.

Where the Open Questions Are

Several genuine unknowns keep this compound interesting rather than settled.

Target hierarchy. With cardiolipin binding and phospholipid scramblase 3 both implicated, the relative contribution of lipid interaction versus defined protein engagement is unresolved.
Preclinical-to-clinical translation. Robust animal effects have not consistently reproduced in larger human studies, and the reasons — exposure, patient selection, endpoint choice, disease stage — are still debated.
Which mitochondrial dysfunction responds. Genetic cardiolipin remodeling defects and acute ischemic injury are very different problems. It is not established which categories of mitochondrial impairment are actually addressable by a membrane-stabilizing peptide.
Ferroptosis mechanism. The link between membrane stabilization and suppression of iron-dependent lipid peroxidation is newly described and not yet mechanistically complete.
Biomarkers. The field still lacks a well-validated, accessible readout of target engagement, which complicates both preclinical design and clinical interpretation.

Researchers approaching SS-31 for the first time are generally best served by reading the 2025 mechanistic reviews first, then the CRISPR target paper, then the TAZPOWER extension — that sequence moves from mechanism to genetic validation to the most mature human dataset available.

Research-grade SS-31 (Elamipretide): Real Peptides supplies SS-31 (Elamipretide) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore SS-31 (Elamipretide) research on Real Peptides

The articles below go deeper on the questions researchers ask most about SS-31 (Elamipretide).

Buying & quality

Research questions

Research timelines & mechanisms

Safety & side effects

Reconstitution, storage & handling

Stacks & comparisons

Legal & regulatory

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Questions

They are the same molecule under different names. SS-31 is the laboratory designation from the Szeto-Schiller peptide series, while elamipretide is the international nonproprietary name adopted during clinical development. Older literature and some supplier catalogs also use MTP-131 or Bendavia. Research papers frequently use SS-31 for preclinical work and elamipretide for clinical studies, but no chemical distinction exists between the terms.

Its alternating aromatic-cationic tetrapeptide structure gives it both positive charge and a hydrophobic face, allowing it to partition into the anionic, cardiolipin-rich inner mitochondrial membrane by direct physicochemical association. This distinguishes it from triphenylphosphonium-conjugated agents, which rely on the mitochondrial membrane potential to accumulate. The distinction matters in experimental models where that potential is already dissipating, such as ischemia-reperfusion injury.

It is generally not characterized as a classical free-radical scavenger. The literature describes it as a membrane-interacting peptide that associates with cardiolipin, helping preserve cristae architecture and electron transport chain organization. Reduced reactive oxygen species output in experimental systems is typically interpreted as a downstream consequence of less electron leak from a better-organized respiratory chain, rather than direct chemical quenching of radicals.

A 2024 genome-wide CRISPR screen published in the Journal of the American Society of Nephrology identified phospholipid scramblase 3 as a biological target of SS-31. Phospholipid scramblase 3 is involved in cardiolipin trafficking between mitochondrial membranes, so the finding is consistent with the lipid-centered mechanistic model while providing a defined protein node that can be tested genetically rather than inferred from phenotype.

Yes. The most developed clinical dataset concerns Barth syndrome, a genetic disorder of cardiolipin remodeling; a 2024 Genetics in Medicine paper reported 168-week open-label extension results from the TAZPOWER study. Clinical work in cardiac indications has also been conducted with mixed outcomes. A 2026 Drugs article documents a first regulatory approval. Research-supplied SS-31 is not an approved product and is for laboratory research use only.'

A useful certificate of analysis is lot-specific and issued by an independent laboratory. It should include an HPLC purity result with the chromatogram visible so peak shape and impurity peaks can be assessed, plus mass spectrometry data confirming the observed mass matches the theoretical mass of the tetrapeptide. Depending on application, water content, acetate content, residual solvents and endotoxin figures may also be relevant.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA